NCT00555594View on ClinicalTrials.gov

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

October 31, 2007

Conditions

Corneal Neovascularization

Interventions

DRUG

Bevacizumab (Avastin)

One dose of 0.1cc of subconjunctival Bevacizumab was applied

Trial Locations (1)

04030

"Asociación Para Evitar la Ceguera en México, IAP, Hospital Dr. Luis Sánchez Bulnes", Mexico City

All Listed Sponsors

collaborator

National Council of Science and Technology, Mexico

OTHER

collaborator

Universidad Nacional Autonoma de Mexico

OTHER

lead

Asociación para Evitar la Ceguera en México

OTHER

NCT00555594 - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization | Biotech Hunter | Biotech Hunter